Axsome Therapeutics (AXSM) Share-based Compensation (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Share-based Compensation data on file, last reported at $23.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 0.56% year-over-year to $23.4 million; the trailing twelve-month figure through Mar 2026 stood at $76.0 million (down 48.73% YoY), and the FY2025 full-year result was $99.1 million, down 32.4% from the prior year.
• Share-based Compensation improved to $23.4 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $133.8 million in Q2 2025 to a low of $9197.0 in Q3 2022.
• A 5-year average of $24.7 million and a median of $16.4 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 99.84% in 2022 and surged 177871.08% in 2023, its largest moves.
• Tracing AXSM's Share-based Compensation over 5 years: stood at $37.4 million in 2022, then slumped by 83.28% to $6.2 million in 2023, then soared by 1209.41% to $81.8 million in 2024, then slumped by 92.53% to $6.1 million in 2025, then soared by 283.6% to $23.4 million in 2026.
• Business Quant data shows AXSM's Share-based Compensation at $23.4 million in Q1 2026, $6.1 million in Q4 2025, and $23.1 million in Q3 2025.